Unexpected Victory: High-Risk Papillary Thyroid Cancer with Distant Metastases Shows Extraordinary Response to First RAI Treatment

被引：0
|
作者：
Rana, Muntaha Fatima [1 ]
Ibrahim, Fatima [1 ]
Hassan, Aamna [1 ]
机构：
[1] Shaukat Khanum Mem Canc Hosp & Res Ctr, Dept Nucl Med, Lahore, Pakistan
来源：
JOURNAL OF THE PAKISTAN MEDICAL ASSOCIATION | 2024年 / 74卷 / 12期
关键词：
Thyroid cancer; lung metastases; excellent response;
D O I：
10.47391/JPMA.24-102
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Papillary Thyroid Cancer (PTC) is the most prevalent type of differentiated thyroid cancer. Its incidence is growing worldwide although it has low death rates. Treatment includes surgery followed by radioactive iodine therapy. Patients are followed up with serum tumour markers (stimulated and unstimulated), sonographically and with iodine I-131 whole body scans. Patients with aggressive metastatic disease have worse prognosis as compared to those with localized disease. We present a case of high-risk PTC with lung metastases, who showed excellent response after the first radioactive iodine therapy.
引用
收藏
页码：2202 / 2203
页数：2
相关论文
共 50 条
  • [41] Prevalence of Distant Metastases in High-Risk Operable Breast Cancer (HROBC) pT1-2 N2a or Higher at Diagnosis
    Parmar, Vani
    Kumar, A. N. Naveena
    Nair, Nita S.
    Joshi, Shalaka
    Thakkar, Purvi
    Chitkara, Garvit
    Ali, Basila
    Gaikwad, Varsha
    Siddique, Shabina
    Vanmali, Vaibhav
    Popat, Palak
    Shah, Sneha
    Desai, Sangeeta
    Shet, Tanuja
    Thakur, Meenakshi
    Rangarajan, Venkatesh
    Badwe, Rajendra Achyut
    INDIAN JOURNAL OF SURGICAL ONCOLOGY, 2024,
  • [42] Prevalence of distant metastases in High-Risk Operable Breast Cancer (HROBC) pT1-2 N2a orhigher at diagnosis
    Parmar, Vani
    Naveena Kumar, A. N.
    Ali, Basila Ameer
    Nair, Nita
    Joshi, Shalaka
    Thakkar, Purvi
    Chitkara, Garvit
    Gaikwad, Varsha
    Vanmali, Vaibhav
    Siddique, Shabina
    Popat, Palak
    Shah, Sneha
    Desai, Sangeeta
    Shet, Tanuja
    Thakur, Meenakshi
    Rangarajan, Venkatesh
    Badwe, Rajendra
    CANCER RESEARCH, 2024, 84 (09)
  • [43] When Can We Discharge Differentiated Thyroid Cancer Patients Who Present With High-Risk Disease and Subsequently Have an Excellent Response to Treatment?
    Mulla, O.
    Seejore, K.
    Gerrard, G. E.
    Gill, V. M.
    Murray, R. D.
    CLINICAL ONCOLOGY, 2019, 31 (10) : 733 - 734
  • [44] Detection of Residual Lymph Node Metastases in High-Risk Papillary Thyroid Cancer Patients Receiving Adjuvant I-131 Therapy The Usefulness of F-18 FDG PET/CT
    Kaneko, Koichiro
    Abe, Koichiro
    Baba, Shingo
    Isoda, Takuro
    Yabuuchi, Hidetake
    Sasaki, Masayuki
    Hatakenaka, Masamitsu
    Honda, Hiroshi
    CLINICAL NUCLEAR MEDICINE, 2010, 35 (01) : 6 - 11
  • [45] The influence of stimulated thyroglobulin and lymphocyte subsets before radioiodine therapy on the therapeutic response in patients with intermediate- and high-risk papillary thyroid carcinoma
    Lu, Chenghui
    Wang, Congcong
    Li, Fengqi
    Liu, Xinfeng
    Wang, Guoqiang
    Li, Jiao
    Wang, Zenghua
    Han, Na
    Zhang, Yingying
    Si, Zengmei
    Wang, Xufu
    CLINICAL AND EXPERIMENTAL MEDICINE, 2023, 23 (06) : 2193 - 2200
  • [46] The influence of stimulated thyroglobulin and lymphocyte subsets before radioiodine therapy on the therapeutic response in patients with intermediate- and high-risk papillary thyroid carcinoma
    Chenghui Lu
    Congcong Wang
    Fengqi Li
    Xinfeng Liu
    Guoqiang Wang
    Jiao Li
    Zenghua Wang
    Na Han
    Yingying Zhang
    Zengmei Si
    Xufu Wang
    Clinical and Experimental Medicine, 2023, 23 : 2193 - 2200
  • [47] The Role of American Thyroid Association Pediatric Thyroid Cancer Risk Stratification and BRAFV600E Mutation in Predicting the Response to Treatment in Papillary Thyroid Cancer Patients ≤18 Years Old
    Senyurek, Yasemin Giles
    Iscan, Yalin
    Sormaz, Ismail Cem
    Poyrazoglu, Sukran
    Tunca, Fatih
    JOURNAL OF CLINICAL RESEARCH IN PEDIATRIC ENDOCRINOLOGY, 2022, 14 (02) : 196 - 206
  • [48] Is TSH suppression still necessary in intermediate- and high-risk papillary thyroid cancer patients with preablation stimulated thyroglobulin <1 ng/mL before the first disease assessment?
    Tian, T.
    Huang, R.
    Liu, B.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (SUPPL 1) : S660 - S660
  • [49] Evolutionary Action Score of TP53 Identifies High-Risk Mutations Associated with Decreased Survival and Increased Distant Metastases in Head and Neck Cancer
    Neskey, David M.
    Osman, Abdullah A.
    Ow, Thomas J.
    Katsonis, Panagiotis
    McDonald, Thomas
    Hicks, Stephanie C.
    Hsu, Teng-Kuei
    Pickering, Curtis R.
    Ward, Alexandra
    Patel, Ameeta
    Yordy, John S.
    Skinner, Heath D.
    Giri, Uma
    Sano, Daisuke
    Story, Michael D.
    Beadlel, Beth M.
    El-Naggar, Adel K.
    Kies, Merrill S.
    William, William N.
    Caulin, Carlos
    Frederick, Mitchell
    Kimmel, Marek
    Myers, Jeffrey N.
    Lichtarge, Olivier
    CANCER RESEARCH, 2015, 75 (07) : 1527 - 1536
  • [50] High Ki-67 LI is an Important Factor for Good Early Outcomes After Radioiodine Therapy in Patients with Intermediate to High-Risk Papillary Thyroid Cancer
    Luo, X.
    Ouyang, W.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S173 - S173
12345